-
NaviFUS begins clinical trial for brain tumour treatment
europeanpharmaceuticalreview
August 06, 2021
NaviFUS? was approved by the Taiwan, China FDA for use in a new clinical trial for the treatment of terminal primary brain tumours.
-
NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors
prnasia
August 04, 2021
NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS?) was recently approved for use in a new clinical trial by the Taiwan, China Food and Drug Administration (TFDA).
-
OncoSynergy Announces First Patient Treated in OS2966 Trial of Recurrent Glioblastoma
americanpharmaceuticalreview
March 10, 2021
OncoSynergy announced the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.
-
PeptiDream and Shionogi sign peptide drug conjugate discovery deal
pharmaceutical-technology
January 24, 2019
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier (BBB) penetrating peptide drug conjugates.
-
Scorpion venom could hold the key to breaching the blood-brain barrier
pharmaceutical-technology
November 26, 2018
The Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a small protein (a peptide) derived from chlorotoxin...
-
Bioasis Announces xB3 ? Platform Technology Licensing Agreement with Prothena
pharmafocusasia
November 05, 2018
Bioasis Technologies Inc., a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ? platform technology for the delivery...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
